 NEW YORK and VIENNA, Austria, April 10, 2021 GLOBE NEWSWIRE -- HOOKIPA Pharma Inc. NASDAQ: HOOK, HOOKIPA, a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive preliminary Phase 1 immunogenicity data for its lead oncology candidates, HB-201 and HB-202, to treat Human Papillomavirus 16-positive HPV16 cancers. The results are from an ongoing Phase 12 study NCT04180215 currently investigating HB-201 as a single-vector therapy and HB-201 and HB-202 as an alternating two-vector therapy for the treatment of advanced metastatic HPV16 cancers. The data were presented today at a late-breaker poster session at the virtual American Association for Cancer Research Annual Meeting. 